Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GZR18 Injection in Healthy Subjects
NCT06548997Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing GZR18 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Dec 2021; status: completed.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06548997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548997.